DOCSLIB.ORG

ACNP 59Th Annual Meeting: Panels, Mini-Panels and Study Groups

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ACNP 59Th Annual Meeting: Panels, Mini-Panels and Study Groups www.nature.com/npp ABSTRACTS COLLECTION ACNP 59th annual meeting: panels, mini-panels and study groups Neuropsychopharmacology (2020) 45:1–67; https://doi.org/10.1038/s41386-020-00889-0 Sponsorship Statement: Publication of this supplement is sponsored by the ACNP. Individual contributor disclosures may be found within the abstracts. Asterisks in the author lists indicate presenter of the abstract at the annual meeting Study Group programs at UCLA and nationally. Dr. Shawn McClintock will present on how inclusion and diversity can be infused into the 1. Inclusion and Diversity Efforts Within Large Scientific continuing education and scientific programs as part of the ACNP Organizations: Tangible Methods: That Work conference, as well as strategies to translate knowledge from the conference to the membership’s place of work. Dr. Sade Spencer April Thames*, Sade Spencer, Lisa Eyler, Shawn McClintock, (co-Chair) will lead an interactive discussion and exercise to Erika Nurmi engage the audience in determining an action intention to take 1234567890();,: back with them to their spheres of influence based on what they Study Group Summary: Owing to the scarcity of women and have learned in the symposium. Overall, this timely and innovative underrepresented minorities in science especially in senior and work group sets the stage within and beyond the ACNP leadership roles, diversity and inclusion are aspirational “buzz- conference to ensure successful integration, implementation, words” that are used widely across institutions, organizational and long-lasting state-of-the-art diversity and inclusion practices. settings, and the scientific community. At federal, state and Disclosure: Nothing to disclose. private sector levels, billions of dollars have been allocated to “fix” this longstanding systemic problem. Unfortunately, there remains no clear consensus on methods deemed effective to improve Study Group institutional diversity and inclusion. Moreover, those who are tasked with initiatives to create systemic change are often 2. Clinical High Risk (CHR) for Psychosis: Where Do We Go members of underrepresented groups who are given many Next? responsibilities, but little to no authority or support. Consequently, these individuals often report feeling as though they are Cheryl Corcoran*, Carrie Bearden, Robin Murray, Raquel Gur, “preaching to the choir” and/or end up sustaining a career cost Scott Woods, Sarah Morris, Brandon Staglin, Michael Sand, from engaging in such efforts. To create lasting change while Yulia Landa, Michael First, Rolando Castillo-Passi, Jerome minimizing burden on underrepresented individuals, it is impor- Taylor, Robert Bilder tant to ensure that efforts to promote diversity and inclusion are evidence-based and rely on methods with demonstrated positive Study Group Summary: The field of research and services on transformation. Given that effective strategies are often based on clinical or ultra-high risk for psychosis (CHR/UHR) has evolved over social psychological and behavioral change theories tested with time, engendering some controversy as to potential ethical clinical trial methodology, it is particularly important for members fi concerns and relative merit. CHR is no longer circumscribed to of scienti c societies, such as the American College of Neurop- risk for psychosis, or even risk itself, as the construct was included sychopharmacology (ACNP), to be aware of optimal practices in “ ” fi in the DSM-5 as Attenuated Psychosis Syndrome (APS), a this area. The proposed study group will introduce speci c “condition for further study”. Ethical concerns about stigma methods, tailored towards fostering inclusion and diversity efforts fi remain and are the focus of empirical research. CHR programs in large scienti c organizations and institutions. Drs. April Thames, exist worldwide, with increased funding for CHR research and Associate Professor of Psychology at the University of Southern services, and sustained efforts for harmonization of research California and Lisa Eyler, Professor of Psychiatry at the University methods and tools. Promising biomarkers of psychosis risk have of California San Diego will discuss methods of enhancing been identified and replicated, however, there is still no evidence- inclusion and diversity efforts from an organizational perspective based pharmacological treatment for CHR. Our study group has that includes developing and sustaining workgroup efforts, fi “ ” representation from NIMH, pharma, charitable nonpro ts, the identifying tangible outcomes and products, use of social media, DSM, the CHR research community, and investigators who can collaboration with international colleagues, and co-advising from contextualize CHR research in the broader effort of early organizational executive leadership. Dr. Erika Nurmi, Associate identification and prevention of schizophrenia. The ACNP com- Professor of Psychiatry at UCLA and Greater Los Angeles VA, will munity is the ideal forum for a discussion of CHR research, and discuss the development and integration of strategies and where to go next. We aim to have a lively discussion in which all activities to promote inclusion and diversity in medical and fi perspectives are presented, with input from presenters and the scienti c education and training; she will present data illustrating audience. There are several questions to consider. (1) One set of successes and challenges in designing and implementing these questions addresses the CHR construct itself. How important is © The Author(s), under exclusive licence to American College of Neuropsychopharmacology 2020 ACNP 59th annual meeting: panels, mini-panels. 2 psychosis outcome, given decreasing rates of transition among mice were injected with AAV-DIO-hM3Dq-mCherry or control CHR worldwide? What are the ramifications for broadening of virus to target excitation of OT neurons in the hypothalamus outcomes of interest in CHR research? While this leads to greater (PVN), or retroAAV-DIO-hM3Dq-mCherry or control virus was focus on comorbidity, cognition, negative symptoms, function and injected to target their projections to the central amygdala recovery, are we moving toward a general psychiatric risk (CeA) and bed nucleus of the stria terminalis (BNST). CNO (3 mg/ construct for young people? What are the roles of healthy and kg) was injected (IP) to activate the excitatory DREADD 30 min patient controls for understanding specificity? Heterogeneity in prior to testing. Mice were injected (IP) with the peripherally- CHR, once considered a threat to validity, is now a research restricted OTR antagonist Atosiban (1 mg/kg) or central OTR priority. Is it worthwhile to consider what features and mechan- antagonist L368,899 (10 mg/kg) 45 min prior to injection of OT isms are common across CHR? How important is risk? What can be (0.5 mg/kg) or vehicle, which was given 30 min prior to testing. done about variability in nomenclature and criteria? How similar Results: Chemogenetic activation of PVN OT neurons reduced should CHR and APS remain, and have we made progress in the binge-like drinking and operant alcohol self-administration, “further study” of the APS “condition”? (2) A second set of mimicking the effects of systemic OT treatment. CNO had no questions focuses on intervention. How do we aggregate effects in mice with control virus. This effect was blocked by promising biomarkers so as to understand mechanisms that pretreatment with L368,899 but not Atosiban in the binge model. may inform treatment? How does academia work with pharma to Activation of PVN OT neurons projecting to BNST or CeA also develop treatments, given the large sample sizes needed to reduced binge-like drinking. The centrally active OTR antagonist address heterogeneity and length of time needed to determine L368,899, but not the peripherally-restricted OTR antagonist outcome? Which outcomes should we focus on? Should we Atosiban, blocked the ability of OT to reduce binge-like drinking integrate pharmacology with the network of coordinated specialty and stress-induced alcohol relapse-like behavior, with females less care for CHR funded by SAMHSA and other funding agencies? (3) responsive to OTR antagonism. A third set of questions address ethical concerns, including limited Conclusions: Chemogenetic activation of OT neurons in the resources. To what extent has the field addressed the problem of PVN reduced alcohol intake in two models in a similar manner as stigma related to CHR? How can we best include in our research systemic administration of the neuropeptide. This effect was planning individuals with lived experience and their families, who reversed by pretreatment with a centrally-active OTR antagonist. are key stakeholders in the CHR research and services endeavor? Also, pharmacological antagonism of OTR in the brain, but not in Also, more broadly, in the context of limits in resources and the periphery, blocked the ability of systemically injected OT to funding, is the CHR approach the most optimal to advance early reduce binge-like drinking and stress-induced reinstatement of identification and prevention of serious mental illness? Namely, alcohol seeking behavior. Finally, targeted activation of PVN OT can advocates of the CHR approach answer the criticism that only neurons that project to CeA and BNST reduced alcohol binge-like a small proportion of individuals who develop a first episode of drinking as well. Collectively, these results suggest that OT effects psychosis have attended CHR services, and therefore a public
Load more

Recommended publications
  • E-Update Tracy J
    John R. Kasich, Governor e-Update Tracy J. Plouck, Director Recovery Promoting Wellness and July 2016 Naloxone Grant Program Results in SFY 2016 Overdose Reversals 2,300 Overdose Reversals in SFY 2016 As reported by county health departments State efforts to make the lifesaving over- Funds were allocated on LAKE ASHTABULA LUCAS WILLIAMS FULTON 15 dose reversal medication naloxone more a per capita basis, with a 78 OTTAWA GEAUGA CUYAHOGA HENRY WOOD ERIE LORAIN accessible to communities throughout Ohio minimum of $1,800 guar- DEFIANCE SANDUSKY 2 83 TRUMBULL 35 62 are showing positive results. According to anteed to each county. SUMMIT P0RTAGE SENECA HURON 22 PAULDING MEDINA 6 PUTNAM HANCOCK 2 MAHONING new data gathered by the Ohio Department According to data 5 ASHLAND WYANDOT CRAWFORD 2 VAN WERT WAYNE of Mental Health and Addiction Services collected by OhioMHAS COLUMBIANA ALLEN 12 RICHLAND STARK 8 HARDIN (OhioMHAS) Office of Quality, Planning research staff, 78 county MARION 17 AUGLAIZE HOLMES CARROLL MERCER 3 47 MORROW and Research, more than 7,800 naloxone public health boards K NOX JEFFERSON LOGAN TUSCARAWAS SHELBY UNION COSHOCTON kits/units were purchased through a grant signed up to participate 4 8 DELAWARE HARRISON CHAMPAIGN 5 1 DARKE program established in the last budget, in the initiative during SFY LICKING MIAMI GUERNSEY BELMONT FRANKLIN MUSKINGUM resulting in 2,363 lives saved. 2016. Of the 10 coun- CLARK 239 2 MONTGOMERY 21 PREBLE MADISON FAIRFIELD NOBLE MONROE The Kasich Administration’s latest bien- ties that did not utilize PERRY GREENE 134 PICKAWAY 1 MORGAN nial budget included $1 million ($500,000 any of the funds, only 6 FAYETTE 5 HOCKING WARREN 4 5 per year) to provide naloxone to all 88 three did not establish BUTLER CLINTON WASHINGTON ROSS 240 9 ATHENS 2 VINTON counties through grants to local health an account with the Ohio HAMILTON HIGHLAND 61 1,159 MEIGS CLER- PIKE 2 authorities.
    [Show full text]
  • Decreased Dopamine Brain Reactivity in Marijuana Abusers Is Associated
    Decreased dopamine brain reactivity in marijuana PNAS PLUS abusers is associated with negative emotionality and addiction severity Nora D. Volkowa,b,1, Gene-Jack Wanga, Frank Telanga, Joanna S. Fowlerc,1, David Alexoffc, Jean Logand, Millard Jaynea, Christopher Wonga, and Dardo Tomasia aLaboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, Rockville, MD 20857; bNational Institute on Drug Abuse, Rockville, MD 20857; cBiosciences Department, Brookhaven National Laboratory, Upton, NY 11973; and dDepartment of Radiology, New York University Langone Medical Center, New York, NY 10016 Contributed by Joanna S. Fowler, June 20, 2014 (sent for review April 9, 2014; reviewed by Bertha Madras, Harvard University Medical School, and Karen Berman, National Institute of Mental Health) Moves to legalize marijuana highlight the urgency to investigate ref. 6). Similarly, cocaine abusers (17, 18) and alcoholics (19, 20), effects of chronic marijuana in the human brain. Here, we chal- but not marijuana abusers (16), show attenuated DA increases in lenged 48 participants (24 controls and 24 marijuana abusers) with striatum when challenged with a stimulant drug, although mar- methylphenidate (MP), a drug that elevates extracellular dopamine ijuana abusers with comorbid schizophrenia or risk for schizo- (DA) as a surrogate for probing the reactivity of the brain to DA phrenia showed blunted DA increases to stimulants (21) and to stimulation. We compared the subjective, cardiovascular, and brain stress (22). However, prior studies are limited by their small DA responses (measured with PET and [11C]raclopride) to MP be- sample sizes (ranging from six to 16 subjects). Also, prior studies tween controls and marijuana abusers.
    [Show full text]
  • Clinical Pharmacology of Daridorexant, a Novel Dual Orexin Receptor Antagonist
    Clinical pharmacology of daridorexant, a novel dual orexin receptor antagonist Inauguraldissertation zur Erlangung der Würde eines Dr. sc. med. Vorgelegt der Medizinischen Fakultät der Universität Basel Von Clemens Mühlan aus 4055 Basel, Schweiz Basel, 2021 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Medizinischen Fakultät auf Antrag von Prof. Dr. Stephan Krähenbühl Prof. Dr. Matthias Liechti Dr. Alexander Jetter Dr. Jasper Dingemanse Basel, 24. Februar 2021 Dekan Prof. Dr. Primo Leo Schär 2 of 118 TABLE OF CONTENTS LIST OF ABBREVIATIONS AND ACRONYMS ............................................................4 ACKNOWLEDGEMENTS .................................................................................................8 SUMMARY .........................................................................................................................9 1 BACKGROUND AND INTRODUCTION ................................................................15 1.1 Insomnia .......................................................................................................15 1.2 The orexin system as a therapeutic target .....................................................18 1.3 Review of orexin receptor antagonists .........................................................20 1.4 Selective vs dual orexin receptor antagonism ..............................................23 1.5 Orexin receptor antagonists available in clinical practice ............................24 1.6 Orexin receptor
    [Show full text]
  • Orexins, Sleep, and Blood Pressure
    Current Hypertension Reports (2018) 20: 79 https://doi.org/10.1007/s11906-018-0879-6 SLEEP AND HYPERTENSION (SJ THOMAS, SECTION EDITOR) Orexins, Sleep, and Blood Pressure Mariusz Sieminski1 & Jacek Szypenbejl1 & Eemil Partinen2,3 Published online: 10 July 2018 # The Author(s) 2018 Abstract Purpose of Review The aim of this review was to summarize collected data on the role of orexin and orexin neurons in the control of sleep and blood pressure. Recent Findings Although orexins (hypocretins) have been known for only 20 years, an impressive amount of data is now available regarding their physiological role. Hypothalamic orexin neurons are responsible for the control of food intake and energy expenditure, motivation, circadian rhythm of sleep and wake, memory, cognitive functions, and the cardiovascular system. Multiple studies show that orexinergic stimulation results in increased blood pressure and heart rate and that this effect may be efficiently attenuated by orexinergic antagonism. Increased activity of orexinergic neurons is also observed in animal models of hypertension. Summary Pharmacological intervention in the orexinergic system is now one of the therapeutic possibilities in insomnia. Although the role of orexin in the control of blood pressure is well described, we are still lacking clinical evidence that this is a possibility for a new approach in the treatment of cardiovascular diseases. Keywords Orexin . Hypocretin . Blood pressure . Sleep . Narcolepsy . Autonomic nervous system Introduction cardiovascular system. With such a variety of functions, orexins appear to be a promising target for therapeutic in- We are celebrating the twentieth anniversary of the discov- terventions aimed at solving the most pivotal health prob- ery of hypocretins/orexins.
    [Show full text]
  • (SBIRT) for Illicit Drug and Alcohol Use at Multiple Healthcare Sites: Comparison at Intake and 6 Months Later Bertha K
    Available online at www.sciencedirect.com Drug and Alcohol Dependence 99 (2009) 280–295 Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and 6 months later Bertha K. Madras a,∗, Wilson M. Compton b, Deepa Avula c, Tom Stegbauer c, Jack B. Stein c, H.Westley Clark c a Harvard Medical School-NEPRC, 1 Pine Hill Drive, Southborough, MA 01772, USA b Division of Epidemiology, Services and Prevention Research, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20892-9561, USA c Substance Abuse and Mental Health Services Administration, Department of Health and Human Service, 1 Choke Cherry Road, Rockville, MD 20857, USA Received 15 April 2008; received in revised form 28 August 2008; accepted 29 August 2008 Available online 16 October 2008 Abstract Objectives: Alcohol screening and brief interventions in medical settings can significantly reduce alcohol use. Corresponding data for illicit drug use is sparse. A Federally funded screening, brief interventions, referral to treatment (SBIRT) service program, the largest of its kind to date, was initiated by the Substance Abuse and Mental Health Services Administration (SAMHSA) in a wide variety of medical settings. We compared illicit drug use at intake and 6 months after drug screening and interventions were administered. Design: SBIRT services were implemented in a range of medical settings across six states. A diverse patient population (Alaska Natives, American Indians, African-Americans, Caucasians, Hispanics), was screened and offered score-based progressive levels of intervention (brief intervention, brief treatment, referral to specialty treatment).
    [Show full text]
  • Royalty Pharma Minerva Press Release January 19 2021
    ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN SELTOREXANT FROM MINERVA NEUROSCIENCES NEW YORK, NY and WALTHAM, MA, January 19, 2021 – Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in additional milestone payments. The additional payments to Minerva will be contingent on the achievement of certain clinical, regulatory and commercialization milestones. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Janssen Pharmaceutica, N.V., a subsidiary of Johnson & Johnson. “We are very pleased to have entered into this agreement with Royalty Pharma, the leader in acquiring pharmaceutical royalties across the life sciences industry,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “The proceeds will be used to fund continued development of roluperidone, the Company’s proprietary lead compound, which is in Phase 3 development to treat negative symptoms in schizophrenia.” “We are delighted to partner with Minerva,” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. “Based on seltorexant’s differentiated mechanism of action and robust clinical evidence to date, we are excited by the therapy’s emerging profile and the opportunity it may bring to address a significant unmet need for the millions of patients with major depressive disorder with insomnia symptoms.” Minerva Neurosciences is entitled to a mid-single digit royalty on worldwide net sales of seltorexant. Cooley acted as legal advisors to Minerva Neurosciences on the transaction.
    [Show full text]
  • Alan Macdiarmid Term Professor Kevin B
    UNIVERSITY OF PENNSYLVANIA Tuesday April 2, 2019 Volume 65 Number 29 www.upenn.edu/almanac Ivan Dmochowski: Alan MacDiarmid Term Professor Kevin B. Mahoney: Ivan Dmochowski, (C’50, HON’99) and Diana T. Vagelos, Penn Chief Executive Officer, University professor of chemis- parents, in honor of longtime Nobel Prize-win- of Pennsylvania Health System try, has been named the ning chemistry professor Dr. Alan MacDiarmid. Kevin B. Mahoney will become the next Alan MacDiarmid Term Dr. P. Roy Vagelos, a chemistry major who CEO of the University of Pennsylvania Health Professor of Chemis- graduated from Penn in 1950 before going on to System (UPHS), Uni- try. Dr. Dmochowski’s receive a medical degree from Columbia Uni- versity of Pennsyl- laboratory develops versity, is the retired chairman and chief execu- vania President Amy chemical and biophysi- tive officer of Merck & Co. He currently serves Gutmann and J. Lar- cal tools to study com- as chairman of the Board at Regeneron Pharma- ry Jameson, executive plex biological systems, ceuticals. Dr. Vagelos served as chair of the Uni- vice president of the including new tech- versity’s Board of Trustees from 1995 to 1999, University of Pennsyl- nologies for biomolec- and he is a former member of the Penn Arts and vania for the Health Ivan Dmochowski ular imaging, identify- Sciences’ Board of Overseers and the former System and dean of ing proteins and RNA molecules important in chair of the Committee for Undergraduate Fi- the Perelman School of brain function, and fabricating functional bio- nancial Aid. Diana T. Vagelos is a former over- Medicine, announced.
    [Show full text]
  • Adoption of NIDA's Evidence-Based
    2012 Adoption of NIDA’s Evidence-Based Treatments in Real World Settings ---A National Advisory Council on Drug Abuse Workgroup Report This report is produced in response to a charge by the NIDA Director for the Workgroup to: 1) Determine how effectively the treatment interventions developed, tested, and evaluated through NIDA’s extramural programs are being transferred and utilized in real world settings (e.g. community treatment centers, primary care settings, criminal justice settings, etc.); 2) Explore barriers for moving from research findings to adoption as standard practice; and 3) Consider whether and how the organization of NIDA could be best structured to meet these evolving scientific goals. National Advisory Council on Drug Abuse National Institute on Drug Abuse i September 6, 2012 ~ UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM Abramson Cancer Center Department of PS)l chiatr~' Anncnbcrg Public Policy Center Caryn Lerman. Ph.D . .."f ar.\' W Ca/kills Pro/l's.WJr lJ epllly /);1'('('(01: Abramso" Callcer Celllt'" July 30, 2012 Nora D. Volkow, M.D., Director National Institute on Drug Abuse 6001 Executive Boulevard Bethesda, MD 20892 Dear Dr. Volkow: I am pleased to transmit the report and recommendations of the National Advisory Council on Drug Abuse Work Group "Adoption 0/ NJDA 's Evidence Based Treatments in Real World Sellings". This Work Group was created at your request in 2011. The report and recommendations reflect the unanimous view of the Work Group members. We take full responsibility for the contents and are available to meet with you and/or members of your staff to discuss our conclusions and recommendations, if needed.
    [Show full text]
  • Commission on Combating Drug Addiction and the Opioid Crisis
    THE PRESIDENT’S COMMISSION ON COMBATING DRUG ADDICTION AND THE OPIOID CRISIS Roster of Commissioners Governor Chris Christie, Chairman Governor Charlie Baker Governor Roy Cooper Congressman Patrick J. Kennedy Professor Bertha Madras, Ph.D. Florida Attorney General Pam Bondi Table of Contents Chairman’s Letter…………………………………………………………………………………5 Summary of Recommendations .................................................................................................... 12 The Drug Addiction and Opioid Crisis ......................................................................................... 19 Origins of the Current Crisis ..................................................................................................... 19 Magnitude and Demographics .................................................................................................. 23 Newly Emerging Threats .......................................................................................................... 26 Pathways to Opioid Use Disorder (Including Heroin) from Prescription Opioids ................... 27 Health, Financial, and Social Consequences ............................................................................. 29 Drug Overdose Deaths .............................................................................................................. 31 Substance Use Treatment Availability ...................................................................................... 32 Systems Approach to Solutions ...............................................................................................
    [Show full text]
  • Leadership Conference on Medical Education in Substance Abuse
    OFFICE OF NATIONAL DRUG CONTROL POLICY Leadership Conference on Medical Education in Substance Abuse “Let us bring to all Americans who struggle with…addiction this message of hope: The miracle of recovery is possible, and it could be you.” President George W. Bush, State of the Union Address, January 20, 2003 Washington, DC December 1-2, 2004 CONFERENCE AGENDA OFFICE OF NATIONAL DRUG CONTROL POLICY LEADERSHIP CONFERENCE ON MEDICAL EDUCATION IN SUBSTANCE ABUSE Washington, DC, December 1-2, 2004 WEDNESDAY, DECEMBER 1, 2004 THURSDAY, DECEMBER 2, 2004 continued 6:00 - 9:00 PM 9:20 - 9:40 am Health Professions Education: 5:00 pm Registration opens (Hotel Mezzanine) The View from NIAAA Ting-Kai Li, M.D. 6:00 pm Dinner Meeting (Consulate Room, Director, National Institute on Mezzanine Level) Alcohol Abuse and Alcoholism 6:00 - 6:10 pm Welcome and Acknowledgments 9:40 - 10:00 am Questions and Discussion Addison D. “Tad” Davis IV (Dr. Volkow & Dr. Li) Acting Deputy Director for Demand Reduction Office of National Drug 10:00 - 10:10 am Overview of the Day and Introduction Control Policy of the Small Group Chairs Mr. Davis & Mrs. Wilford 6:10 - 7:00 pm Dinner (generously sponsored by The Robert Wood Johnson Foundation) 10:15 - 10:30 am Break 7:00 - 7:10 pm Introduction of the Panelists (Mr. Davis) 10:30 - 12:00 pm Small Groups Meet — Session 1 Group 1 (Undergraduate Medical Education) 7:10 - 8:00 pm Panel Discussion Dr. Bertha K. Madras, Group 2 (Graduate Medical Education) Dr. Sheldon Miller, Dr. Mark L. Kraus Group 3 (Continuing Medical Education) 8:00 - 8:30 pm Questions and Discussion 12:00 - 12:50 pm Working Lunch 8:30 - 9:00 pm Overview of Thursday’s Activities and 12:50 - 1:10 pm Health Professions Education: Adjourn for the Evening The View from NHTSA Mr.
    [Show full text]
  • ABSTRACTS Asilomar Hotel Conference Grounds FIFTY-FIRST ASILOMAR CONFERENCE on SIGNALS, SYSTEMS & COMPUTERS
    FIFTY-FIRST ASILOMAR CONFERENCE ON SIGNALS, SYSTEMS, AND COMPUTERS OCTOBER 29–NOVEMBER 1, 2017 FINAL PROGRAM & ABSTRACTS Asilomar Hotel Conference Grounds FIFTY-FIRST ASILOMAR CONFERENCE ON SIGNALS, SYSTEMS & COMPUTERS Technical Co-sponsor IEEE SIGNAL PROCESSING SOCIETY CONFERENCE COMMITTEE General Chair Finance Chair Geert Leus Ric Romero* Delft University of Technology Department of Electrical & Mekelweg 4, 2628 CD Computer Engineering Delft, The Netherlands Naval Postgraduate School [email protected] Monterey, CA 93943-5121 [email protected] Technical Program Chair Joseph Cavallaro Electronic Media Chair Dept. of Electrical and Computer Marios Pattichis Engineering, Center for Multimedia Department of Electrical & Computer Communication Engineering Rice University MSC01 1100, 1 6100 Main Street, MS 380 University of New Mexico Houston, TX 77005, USA Albuquerque, NM 87131-0001 [email protected] [email protected] Conference Coordinator Student Paper Contest Chair Monique P. Fargues* Scott Acton Department of Electrical & Electrical & Computer Eng. Dept. Computer Engineering University of Virginia Naval Postgraduate School P.O. Box 400743 Monterey, CA 93943 Charlottesville, VA 22904-4743 [email protected] [email protected] Publications Chair Student Paper Contest Co-Chair Michael B. Matthews Anna Scaglione NorthWest Research Associates Ira A. Fulton Schools of Engineering, 301 Webster Street School of Electrical, Computer, and Monterey, CA 93940 Energy Engineering [email protected] Arizona State University Tempe, AZ 85287-5706 Publicity Chair [email protected] Linda S. DeBrunner Department of Electrical & Computer Engineering Florida State University Tallahassee, FL 32310-6046 [email protected] *participating in his or her personal capacity 1 Welcome from the General Chairman Prof.
    [Show full text]
  • Tackling Insomnia As Part of the Complete Approach to Mental Healthcare
    Tackling Insomnia as Part of the Complete Approach to Mental Healthcare Karl Doghramji, MD Professor of Psychiatry, Neurology, and Medicine Medical Director, Jefferson Sleep Disorders Center Thomas Jefferson University Philadelphia, Pennsylvania Educational grant support was provided from Eisai. Faculty Disclosure • Dr. Doghramji: Consultant—Eisai, Purdue, Merck, Pfizer; Stock—Merck. Disclosure • The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational use(s) of drugs, products, and/or devices (any use not approved by the US Food and Drug Administration). – Dr. Doghramji will be discussing off-label use of medications in this presentation and will identify those medications. • Applicable CME staff have no relationships to disclose relating to the subject matter of this activity. • This activity has been independently reviewed for balance. Learning Objectives • Discuss the relationship between insomnia and comorbid psychiatric disorders and the resulting implications for diagnosis and co-treatment • Evaluate current guideline recommendations for insomnia management with respect to the present standard of care and unmet needs with existing therapies • Review the latest clinical data surrounding the mechanisms of action and risk/benefit profiles of emerging pharmacotherapies for insomnia for informed therapeutic decision-making Mr. A • 58-year-old accountant, c/o unrefreshing sleep • Onset 4 months ago • Frequency 4 to 5 nights/week • Mind “spins” at bedtime • Feels washed out during day; low energy • Moody, irritable • Curtailed social activities • Medical history: Hypertension, controlled with losartan • Exam: Nl vital signs, BMI 38 • MSE: Psychomotor slowing; mood “fine”. Affect restricted, no h/s ideation, sensorium clear. Cognitive functions intact • Recent blood tests, including CBC, blood chemistry tests, LFTs, and TSH are WNL What additional criterion must be met to satisfy criteria for DSM-5 insomnia disorder? 1.
    [Show full text]